# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6989636

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
NOVARTIS AG	06/15/2016

# **RECEIVING PARTY DATA**

Name:	GLAXOSMITHKLINE BIOLOGICALS SA		
Street Address:	RUE DE L'INSTITUT 89		
City:	RIXENSART		
State/Country:	BELGIUM		
Postal Code:	B-1330		

# **PROPERTY NUMBERS Total: 1**

Property Type	Number	
Application Number:	16274822	

# **CORRESPONDENCE DATA**

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: us\_cipkop@gsk.com

Correspondent Name: GLAXOSMITHKLINE GLOBAL PATENTS UP4110

Address Line 1: 1250 SOUTH COLLEGEVILLE ROAD COLLEGEVILLE, PENNSYLVANIA 19426

ATTORNEY DOCKET NUMBER: VN53615D2	
NAME OF SUBMITTER:	ABIGAIL HEDLEY
SIGNATURE:	/Abigail Hedley/
DATE SIGNED:	10/26/2021

**Total Attachments: 2** 

source=VN53615D2 US Assignment\_NAG to GSK Bio#page1.tif source=VN53615D2 US Assignment NAG to GSK Bio#page2.tif

PATENT 506942799 REEL: 057917 FRAME: 0844

# CONFIRMATORY ASSIGNMENT

WE, NOVARTIS AG a company limited by shares duly incorporated in Switzerland and whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland do hereby dcclare that we are the sole owner of the following patents/ patent applications entitled "PURIFICATION" OF STAPHYLOCOCCUS AUREUS TYPE 5 AND TYPE 8 CAPSULAR POLYSACCHARIES".

Country	<b>Application Date</b>	<b>Application Number</b>	<b>Grant Date</b>	Patent Number
Australia	01 <b>-</b> Nov-10	2010310919	20-Aug-15	2010310919
Brazil	01-Nov-10	BR1120120102230		
Canada	01-Nov-10	2779578		
China P R	01-Nov-10	201080060554 0		
European Patent Convention	01-Nov-10	10782040 9		
Japan	01-Nov-10	2012-536006	08-Apr-16	5914344
Japan	30-Dec-15	2015-257722		
Mexico	17-Dec-15	MX/a/2015/017594		
Mexico	01-Nov-10	MX/A/2012/004851	18-Dec-15	335875
Russian Federation	01-Nov-10	2012122237	10-Apr-16	2579900
Singapore	30-Oct-14	10201407096R	25-Apr-16	10201407096R
United States	15 <b>-Ma</b> y-15	14/714097		
United States	01-Nov-10	13/504920	23-Jun-15	9060965

And in accordance with the Intellectual Property Assignment Agreement dated 2 March 2015 between NOVARTIS AG and GLAXOSMITHKLINE BIOLOGICALS SA, for good and valuable consideration, the receipt of which is hereby acknowledged, we NOVARTIS AG have assigned the entire right, title and interest and from which priority may be claimed from one or more applications, or any division, continuation and continuation-in-part of said application to in and to said patent application and all countries in which this/ these application(s) are filed to GLAXOSMITHKLINE BIOLOGICALS SA of Rue de l'Institut 89, 1330 Rixensart, Belgium

Dated this 15 day of June 2016

Signed for and on behalf of

**NOVARTIS AG** 

Lorraine B. Ling Authorized Signatory on behalf of NOVARTIS AG

**NOVARTIS AG** 

Authorized Signatory on behalf of

**PATENT REEL: 057917 FRAME: 0845**  VN53615

Signed for and on behalf of

GLAXOSMITHKLINE BIOLOGICALS SA

Wıllıam R. Majarian

Authorized Official on behalf of

GLAXOSMITHKLINE BIOLOGICALS SA

PATENT REEL: 057917 FRAME: 0846

**RECORDED: 10/26/2021**